12:00 AM
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Zybrestat fosbretabulin: Phase II started

OxiGene said the Gynecologic Oncology Group (GOG) began an open-label Phase II trial to compare IV Zybrestat plus IV Avastin bevacizumab every 21 days vs. Avastin alone in...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >